



Pfizer Inc.

275 North Field Drive

Lake Forest, IL 60045

October 6, 2026

ZHOPL Facility Flooding Supply Impact Update

Dear Valued Customer,

Pfizer U.S. Hospital and Biosimilars is committed to providing timely supply information so that you can plan for patient care. As a follow up to our [August communication](#) regarding the severe flooding that impacted the Zydus Hospira Oncology Private Limited (ZHOPL) manufacturing facility in Gujarat, India, we want to provide an update on the manufacturing site status, product availability, and estimated supply recovery.

Manufacturing Site Recovery:

The site remains closed as our teams continue comprehensive assessments across the facility to determine the full scope of work needed to safely resume operations in compliance with Good Manufacturing Practices (GMP) standards required for an aseptic manufacturing site. The ZHOPL facility sits at a lower elevation than much of the surrounding area, contributing to the extent of damage the facility sustained, including impact to the laboratories, manufacturing areas, and equipment. **Given the extensive damage, the current best-case estimate is that new supply will be available in a phased approach beginning in mid-to-late 2028.**

The FDA and other relevant organizations have been informed of our supply recovery estimates, which reflect the information available today and may be updated as our assessments and

remediation efforts progress in the future. In parallel, we are evaluating alternate sites within our global manufacturing network and third-party manufacturing operations to help mitigate the impact on supply where possible. We understand these critical medications are of great importance for patients, and we are putting every effort behind restoring product supply through a variety of channels.

Current Supply Availability:

With the extended recovery estimate timeline established, we have made the decision to remove the product allocations initiated in August and will support purchasing at historical demand, while product remains available.

No new shipments are planned, and customers are encouraged to begin identifying alternate sources of supply where possible, to support patient care as we work to restore product supply. To help customers plan for patient care, below is an Appendix of impacted products and our currently estimated supply status as of October 6, 2026.

Supply status is based on historical demand and may be subject to change as market dynamics evolve. We are working in partnership with our wholesalers and distributors to ensure responsible downstream distribution of product, while available. Contact your trading partner directly for availability. To place a Direct Order on short-dated product, you can contact Customer Service at 1-844-646-4398 or order via [Pfizer Prime](#) (as a reminder, when using Pfizer Prime, the “EA” is the Unit of Sale (UoS) size).

For the latest information, we encourage you to check our [Availability Report](#), updated frequently and accessible on [PfizerHospitalUS.com](#). All available impacted sterile injectables oncology products have been adjusted to ‘Limited Supply’ on the AV Report, which is intended to facilitate a responsible approach to fulfill demand, ensure equitable distribution, and allow adequate time to transition to alternative suppliers before an eventual depletion. Pfizer is committed to regular supply availability updates as inventory depletes, which will be shared through your Pfizer representative.

For additional product availability questions, please contact your Pfizer sales representative or Health System Directors. Alternatively, the Supply Continuity Team can be contacted between 7 a.m. and 5 p.m. (CT) at 1-844-646-4398 (select option 1 [Customer], then option 3 [Supply

Continuity Team]). For medical inquiries, please contact Pfizer Medical Information at 1-800-438-1985.

We appreciate your patience, partnership, and sincere support for our mutual goal of continuity of patient care during this time.

Thank you,

Adam Van Eperen

U.S. Hospital Portfolio Lead

Pfizer Global Hospital & Biosimilars, U.S. Commercial

Appendix of Pfizer Inventory Estimates as of 10/6/2026:

NDC	Product Description	Unit of Sale Size	Remaining Inventory Levels (projected as of 10/6/2026)
61703-0332-18	Bleomycin for Injection, USP 15 Units Single Dose ONCO-TAIN™ Glass Fliptop Vial	1	9 to 12 Months
61703-0323-22	Bleomycin for Injection, USP 30 Units Single Dose ONCO-TAIN™ Glass Fliptop Vial	1	3 to 6 Months
00009-7529-10	Camptosar® (Irinotecan Hydrochloride Injection, USP) 40 mg/2 mL (20 mg/mL) ONCO-TAIN® Single Dose Glass Fliptop Vial	1	3 to 6 Months
00009-0112-05	Camptosar® (Irinotecan Hydrochloride Injection, USP) 100 mg/5 mL (20 mg/mL) ONCO-TAIN® Single Dose Glass Fliptop Vial	1	3 to 6 Months
00009-0082-02	Camptosar® (Irinotecan Hydrochloride Injection, USP) 300 mg/15 mL (20 mg/mL) ONCO-TAIN® Single Dose Glass Fliptop Vial	1	< 3 Months
61703-0305-38	Cytarabine Injection 100 mg/5 mL (20 mg/mL) Single Dose ONCO-TAIN™ Glass Fliptop Vial	5	< 3 Months
61703-0304-36	Cytarabine Injection 500 mg/25 mL (20 mg/mL) Multiple Dose ONCO-TAIN® Glass Fliptop Vial	1	< 3 Months
61703-0303-46	Cytarabine Injection 1,000 mg/50 mL (20 mg/mL) Pharmacy Bulk Package ONCO-TAIN® Glass Vial	1	< 3 Months
61703-0319-22	Cytarabine Injection 2 g/20 mL (100 mg/mL) Single Dose ONCO-TAIN® Glass Fliptop Vial	1	3 to 6 Months
00409-0201-02	Docetaxel Injection, USP 20 mg/2 mL (10 mg/mL) Single Dose ONCO-TAIN® Glass Fliptop Vial	1	< 3 Months
00409-0201-10	Docetaxel Injection, USP 80 mg/8 mL (10 mg/mL) Multiple Dose ONCO-TAIN® Glass Fliptop Vial	1	< 3 Months

NDC	Product Description	Unit of Sale Size	Remaining Inventory Levels (projected as of 10/6/2026)
00409-0201-20	Docetaxel Injection, USP 160 mg/16 mL (10 mg/mL) Multiple Dose ONCO-TAIN® Glass Fliptop Vial	1	< 3 Months
00409-0366-01	Docetaxel Injection, USP 20 mg/mL Single Dose ONCO-TAIN® Glass Fliptop Vial	1	< 3 Months
00409-0367-01	Docetaxel Injection, USP 80 mg/4 mL (20 mg/mL) Multiple Dose ONCO-TAIN™ Glass Fliptop Vial	1	< 3 Months
00409-0368-01	Docetaxel injection, USP 160 mg/8 mL (20 mg/mL) Multiple Dose Glass Vial	1	3 to 6 Months
00069-0358-20	DOXOrubicin Hydrochloride Injection, USP 10 mg/5 mL (2 mg/mL) Single Dose ONCO-TAIN® Glass Fliptop Vial	1	6 to 9 Months
00069-0277-02	DOXOrubicin Hydrochloride Injection, USP 20 mg/10 mL (2 mg/mL) Single Dose ONCO-TAIN® Glass Fliptop Vial	1	< 3 Months
00069-0343-02	DOXOrubicin Hydrochloride Injection, USP 50 mg/25 mL (2 mg/mL) Single Dose ONCO-TAIN® Vial	1	Depleted
00069-1542-20	DOXOrubicin Hydrochloride Injection, USP 200 mg/100 mL (2 mg/mL) Multiple Dose ONCO-TAIN® Glass Fliptop Vial	1	< 3 Months
00009-5091-25	Ellence™ (epirubicin hydrochloride injection) 50 mg/25 mL (2 mg/mL) ONCO-TAIN® Single Dose Glass Fliptop Vial	1	3 to 6 Months
00009-5093-10	Ellence™ (epirubicin hydrochloride Injection, USP) 200 mg/mL 100 mL (2 mg/mL) ONCO-TAIN® Single Dose Glass Fliptop Vial	1	6 to 9 Months
00409-0183-01	Gemcitabine Injection 200 mg/5.26 mL (38 mg/mL) Single Dose ONCO-TAIN® Glass Fliptop Vial	1	3 to 6 Months

NDC	Product Description	Unit of Sale Size	Remaining Inventory Levels (projected as of 10/6/2026)
00409-0185-01	Gemcitabine for Injection, USP 200 mg ONCO-TAIN® Single Dose Glass Fliptop Vial	1	< 3 Months (short dated, expiry 3/31/2027)
00409-0181-01	Gemcitabine Injection 1 g/26.3 mL (38 mg/mL) Single Dose ONCO-TAIN® Glass Fliptop Vial	1	3 to 6 Months
00409-0186-01	Gemcitabine for Injection, USP 1 g ONCO-TAIN® Single Dose Glass Fliptop Vial	1	3 to 6 Months
00409-0182-01	Gemcitabine Injection 2 g/52.6 mL (38 mg/mL) Single Dose ONCO-TAIN® Glass Fliptop Vial	1	3 to 6 Months
00409-0187-01	Gemcitabine for Injection, USP 2 g ONCO-TAIN® Single Dose Glass Fliptop Vial	1	3 to 6 Months
00013-2576-05	Idamycin PFS® (idarubicin hydrochloride injection) 5 mg/5 mL (1 mg/mL) ONCO-TAIN® Single Dose Glass Fliptop Vial	1	> 12 Months
00013-2586-10	Idamycin PFS® (idarubicin hydrochloride injection) 10 mg/10 mL (1 mg/mL) ONCO-TAIN® Single Dose Glass Fliptop Vial	1	6 to 9 Months
00013-2596-20	Idamycin PFS® (idarubicin hydrochloride injection) 20 mg/20 mL (1 mg/mL) ONCO-TAIN® Single Dose Glass Fliptop Vial	1	> 12 Months
61703-0349-16	Irinotecan Hydrochloride Injection, USP, 40 mg/2 mL (20 mg/mL) Single Dose ONCO-TAIN® Glass Fliptop Vial	1	< 3 Months (short dated only, expiry 1/31/2027)
61703-0349-09	Irinotecan Hydrochloride Injection, USP, 100 mg/5 mL (20 mg/mL) Single Dose ONCO-TAIN® Glass Fliptop Vial	1	3 to 6 Months
61703-0349-36	Irinotecan Hydrochloride Injection, USP, 500 mg/25 mL (20 mg/mL) Single Dose ONCO-TAIN® Glass Fliptop Vial	1	3 to 6 Months

NDC	Product Description	Unit of Sale Size	Remaining Inventory Levels (projected as of 10/6/2026)
61703-0343-18	Mitoxantrone Injection, USP 20 mg/10 mL (2 mg/mL) Multiple Dose ONCO-TAIN® Glass Fliptop Vial	1	< 3 Months
61703-0343-65	Mitoxantrone Injection, USP 25 mg/12.5 mL (2 mg/mL) Multiple Dose ONCO-TAIN® Glass Fliptop Vial	1	< 3 Months (short dated only, expiry 2/28/2027)
61703-0343-66	Mitoxantrone Injection, USP 30 mg/15 mL (2 mg/mL) Multiple Dose ONCO-TAIN® Glass Fliptop Vial	1	< 3 Months (short dated only, expiry 2/28/2027)
00409-0801-01	Nipent™ (pentostatin for injection) 10 mg Single Dose ONCO-TAIN® Glass Fliptop Vial	1	Depleted
61703-0363-18	Oxaliplatin Injection 50 mg/10 mL (5 mg/mL) Single Dose ONCO-TAIN® Glass Fliptop Vial	1	< 3 Months
61703-0363-22	Oxaliplatin Injection 100 mg/20 mL (5 mg/mL) Single Dose ONCO-TAIN® Glass Fliptop Vial	1	3 to 6 Months
00409-1045-01	Pemetrexed Injection 100 mg/4 mL (25 mg/mL) Single Dose Vial	1	< 3 Months
00409-2188-01	Pemetrexed Injection 500 mg/20 mL (25 mg/mL) Single Dose Vial	1	< 3 Months
00409-3532-01	Pemetrexed Injection 1 g/40 mL (25 mg/mL) Single Dose Vial	1	< 3 Months
00409-0302-01	Topotecan Injection 4 mg/4 mL (1 mg/mL) Single Dose ONCO-TAIN® Glass Fliptop Vial	1	< 3 Months

